Loading quotes...

Forecast

The analysts' average price target is €33.31 (+339.45%). The median is €24.99 (+229.68%).

Buy	7
Hold	27
Sell	2

News Go to news feed

Supernus completes acquisition of Sage Therapeutics

Supernus Pharmaceuticals has completed the acquisition of Sage Therapeutics for $8.50 per share, expanding its portfolio with a fourth growth product. The transaction includes a potential additional value right of up to $3.50 per share, contingent on certain milestones. Sage will operate as a wholly owned subsidiary of Supernus, and the acquisition is expected to contribute positively to earnings starting in 2026. » More on de.investing.com
Supernus receives antitrust clearance for acquisition of Sage Therapeutics

Supernus Pharmaceuticals has successfully completed the antitrust waiting period for its planned acquisition of Sage Therapeutics, clearing a key hurdle. The transaction, valued at up to $795 million, includes a cash payment and additional contingent value rights for Sage shareholders. Upon completion, Sage will become a wholly owned subsidiary of Supernus and will be delisted from NASDAQ. » More on de.investing.com

Financials

In the last quarter, Sage Therapeutics had revenue of €26.86m and net profit of -€42.13m

(EUR)	June 2025	YoY
Revenue	26.86m	-
Gross profit	26.91m	-
Net profit	-42.13m	-
EBITDA	-45.9m	-

Fundamentals

Metric	Value
Market capitalization	€486.31m
Number of shares	62.78m
52-week high/low	€8.35 - €4.12
Dividends	No
Beta	0.30
P/E ratio	-1.32
PEG ratio	-0.04
P/B ratio	1.13
P/S ratio	13.21

Company profile

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.